Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05023018 | NEO100 and High-Grade Meningioma | PHASE2 | RECRUITING | 30 | — | — | Jul 1, 2022 | Jun 30, 2027 | Mar 2, 2026 | 3 | United States |
Progression free survival
| Arm | Type | Description |
|---|---|---|
| Patients with high-grade meningioma | EXPERIMENTAL | 30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma |
| Name | Type | Description |
|---|---|---|
| NEO100 | DRUG | NEO100 is a purified form of perillyl alcohol. |
Inclusion Criteria Patient must: 1. Have histologically confirmed WHO Grade II or III meningioma that is residual, progressive or recurrent following at least minimally safe resection and radiation therapy. Metastatic meningiomas are allowed. 1. Residual disease is defined as residual measurab...